1. Pink Sheet
  2. >>Geography
  3. >>Europe

CorMedix Launches Catheter Lock Product In Germany, Looks Ahead To U.S.

The company is shipping Neutrolin, a device containing an antimicrobial/antifungal agent and two anti-clotting agents, in Germany to “lock” catheters between dialysis sessions and prevent blood stream infections and clots. The New Jersey firm also is working with FDA to get the product approved in the U.S. as a specialty pharmaceutical.

It’s been a long time getting to market for CorMedix Inc.’s Neutrolin since the company licensed the product in 2008, but the product, which can prevent blood stream infections and clots in central venous catheter-using patients, is being shipped to dialysis centers in Germany now. CorMedix is also in discussions with FDA about a regulatory path forward for Neutrolin as a specialty pharmaceutical product in the U.S.

Bridgewater, N.J.-based CorMedix obtained worldwide development, manufacturing and marketing rights to Neutrolin from ND Partners LLC in February 2008 when...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Germany

More from Europe

Valneva Expects UK And France to Lift Ixchiq Age Restriction Following EMA Decision

 
• By Anabel Costa-Ferreira

Other authorities are expected to mirror the European Medicines Agency’s decision to lift the temporary restriction it placed on using Valneva’s chikungunya vaccine in people aged 65 years and older.

UK’s Plan To Become World’s Third Top Life Sciences Economy Falls Short, Says ABPI

 
• By Neena Brizmohun

The Association of the British Pharmaceutical Industry says that while the government’s newly published Life Sciences Sector Plan includes many positive commitments, they are not enough.

EMA Sets New Priorities As Number Of RWE Studies Climbs 48%

 
• By Eliza Slawther

Real-world data studies conducted by the European Medicines Agency increased by 48% according to its latest report on the topic, prompting the agency to consider how it can better integrate this type of evidence into regulatory decision-making.